[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Severe illness after vaccination", "description": "Hospitalisation among vaccine breakthrough COVID-19 infections\n\nhttps://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00558-2/fulltext\n\nRobust vaccine efficacies at preventing severe symptomatic disease\n\nBreakthrough SARS-CoV-2 infections in fully vaccinated\n\nhttps://covid.joinzoe.com/post/worryingly-close-to-100-000-new-cases-a-day\n\nImpact of vaccination on admission to hospital\n\nPatients with confirmed SARS-CoV-2 infection\n\nYale New Haven Health System, Connecticut\n\nBetween March 23 and July 1, 2021\n\nPatients were considered fully vaccinated 14 days after second dose\n\n969 patients were admitted PCR positive\n\n172 (18%) of 969 patients had received at least one vaccine dose\n\n103 had received a partial vaccine course\n\n15 had received a complete course\n\n54 were fully vaccinated\n\nAmong the 54\n\n25 (46%) patients were asymptomatic\n\n4 (7%) had mild disease\n\n11 (20%) had moderate disease\n\n14 (26%) had severe or critical illness\n\n4 (7%) required ICU\n\n1 required ventilation\n\n3 died\n\nAmong those with severe or critical illness\n\nMedian age 80\u00b75 years\n\nPre-existing comorbidities in the 14 patients with severe or critical illness\n\nBody\u2013mass index more than 25 kg/m\u00b2 (n=9)\n\nCardiovascular disease (n=12)\n\nLung disease (n=7)\n\nMalignancy (n=4)\n\nType 2 diabetes (n=7)\n\nImmunosuppressive agent (n=4)\n\nDifference between vaccines\n\n13 of 14 patients had received BNT162b2, Pfizer\n\n1 of the 14 had received mRNA-1273, Moderna\n\n0 of the 14 had received Ad.26. COV2.S, J and J\n\nMay 17, 2021, vaccine doses in Connecticut\n\nPfizer, 1, 358, 175\n\nModerna, 1, 044, 420\n\nJ and J, 267, 000", "link": "https://www.youtube.com/watch?v=vOyB2PyRf-k", "date_published": "2021-10-31 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Antidepressant reduces hospitalisations and deaths", "description": "Common antidepressant, $4 per course and it works\n\nEffect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial\nhttps://clinicaltrials.gov/ct2/show/NCT04727424\n\nhttps://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltext\n\nhttps://www.togethertrial.com\n\nBackground\n\nPotential therapeutic role of fluvoxamine\n\nTOGETHER trial for acutely symptomatic patients\n\nTo assess the efficacy of fluvoxamine versus placebo\n\nIn preventing hospitalisation \n\nMethods\n\nPlacebo-controlled\n\nRandomised\n\nDouble blind\n\nAdaptive platform trial\n\n(Factoring in analyses at key points\n\nSo study design parameters like sample size, dosage, or patient selection can be adjusted accordingly)\n\nhttps://www.parexel.com/experience/adaptive-flexible-trials?KW=adaptive%20trial%20design&AG=%7Badgroup%7D&CS=MSS&utm_source=google&utm_medium=paid&utm_campaign=mss&utm_term=adaptive%20trial%20design&utm_content=106310559248&gclid=CjwKCAjw2vOLBhBPEiwAjEeK9t9AW3N8ysMeIkLgKabG5MRPEtJD9EJsq8hzBhnQ0ztDLPPUm5gppBoCe_oQAvD_BwE\n\nHigh-risk symptomatic Brazilian adults\n\nAge ranges and 58% female\n\nConfirmed positive for SARS-CoV-2\n\nWithin 7 days from first symptoms or diagnosis\n\nPatients from 11 clinical sites in Brazil\n\nPatients were randomly assigned (1:1)\n\nFluvoxamine (100 mg twice daily for 10 days), n = 741\n\nPlacebo, n = 756\n\nPrimary outcome\n\nHospitalisation, retention or transfer\n\nUp to 28 days post-random assignment\n\nFindings, Jan 20 to Aug 5, 2021\n\nThe proportion of patients observed in a COVID-19 emergency setting for more than 6 h\n\nOr transferred to a teritary hospital due to COVID-19 (87%)\n\nLower for the fluvoxamine group compared with placebo\n\nFluvoxamine group\n\n79 [11%] of 741\n\nPlacebo group\n\n119 [16%] of 756\n\nRelative risk 0\u00b768\n\n95% credible interval, 0\u00b752\u20130\u00b788\n\nProbability of superiority, 99\u00b78%\n\nFluvoxamine group\n\n17 deaths\n\nPlacebo group\n\n25 deaths\n\nOdds ratio [OR] 0\u00b768\n\n95% credible interval, 0\u00b736\u20131\u00b727\n\nNo significant differences in number of treatment emergent adverse events among patients in the fluvoxamine and placebo groups\n\nFluvoxamine group\n\n84 stopped taking\n\nPlacebo group\n\n64 \n\nThe absolute number of serious adverse events associated with fluvoxamine was lower than for placebo\n\nthis might reflect the modulatory effect of fluvoxamine on systemic inflammation\n\nMechanism?\n\nAnti-inflammatory\n\nPreventing cytokine storm\n\nAntiplatelet activity\n\nIncreasing plasma levels of melatonin\n\nIt is now crucial to establish whether a class effect exists?\n\nInteractions with vaccines, improved effect?\n\n stopped taking\n\nhttps://bnf.nice.org.uk/drug/fluvoxamine-maleate.html\n\n\nFor Adult \n\nInitially 50\u2013100\u202fmg daily", "link": "https://www.youtube.com/watch?v=qrYj5VJKLIs", "date_published": "2021-10-30 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]